Live tape
Top 8, mentions 7d17,305MSFT3,274 mentions▲ +0.08GOOGL2,648 mentions▲ +0.05META2,209 mentions▲ +0.04AAPL2,204 mentions▲ +0.07SPCX1,987 mentions▲ +0.06SNDK1,823 mentions▲ +0.06NVDA1,742 mentions▲ +0.07QQQ1,418 mentions▲ +0.04

Equity · Healthcare

ROIV

Roivant Sciences Ltd. · NasdaqGS

$34.52 +1.74% 1D Finazon · prior-day close · Jul 17, 2026
Price · Chart Chart by TradingView
Track this symbol on TradingView

The chart above plots the price of ROIV over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 56 sessions over that window: $27.84 on 1 May 2026 through $34.52 on 17 July 2026. Finazon · prior-day close.

Market cap $24.8B
52-week range $11.00 – $36.80
Avg volume 1.3M

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Jul 29, 2026

ROIV insider trades

SEC Form 4 · last 90 days · newest reported trade 27 Jul 2026
Open-market buys 0
Open-market sells 7
Net sold $54.74M
Non-trade filings 17
Date Insider Type Shares Value
27 Jul 2026 Venker Eric President & Immunovant CEO Sell 200,000 $6.99M
30 Jun 2026 Fitzgerald Meghan Director Sell 10,000 $349K
29 Jun 2026 Epperly Melissa B, Director Sell 17,750 $610K

Showing the 12 most recent of 24 filings in this window. The figures above count all of them.

Compensation mechanics (9 filings)

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
27 Jul 2026 Venker Eric President & Immunovant CEO Option exercise 200,000 $770K
17 Jul 2026 Epperly Melissa B, Director Award 543
17 Jul 2026 MOMTAZEE JAMES C Director Award 405
17 Jul 2026 Oren Ilan Director Award 775
30 Jun 2026 Fitzgerald Meghan Director Option exercise 10,000 $88K
30 Jun 2026 Gline Matthew CEO Tax withheld 76,171 $2.70M
30 Jun 2026 Sukhatme Mayukh President & CIO Tax withheld 46,878 $1.66M
30 Jun 2026 Torti Frank President and Vant Chair Tax withheld 40,310 $1.43M
29 Jun 2026 Epperly Melissa B, Director Option exercise 17,750 $79K

ROIV reported financials

SEC EDGAR XBRL

ROIV reported revenue of $8.3M for the fiscal year ended 31 Mar 2026. Net income over the same period was −$299.8M.

Figure Reported Period
Revenue $8.3M 31 Mar 2026 fiscal year
Net income −$299.8M 31 Mar 2026 fiscal year
Diluted EPS −$0.54 31 Mar 2026 fiscal year
Total assets $5.7B 31 Mar 2026 at period end
Total equity $4.5B 31 Mar 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 31 Mar 2026

ROIV earnings

SEC EDGAR
Date Period EPS Revenue
31 Mar 2026 FY 2025 $-0.54 $8M
31 Dec 2025 Q3 2025 $-0.38 $2M
30 Sep 2025 Q2 2025 $-0.17 $2M
30 Jun 2025 Q1 2025 $-0.33 $2M

Reported figures & scheduled dates · SEC EDGAR filings

ROIV institutional holders

SEC Form 13F

10 of the 45 institutional funds we track reported a ROIV position for the quarter ended 31 Mar 2026 — a combined $766.9M; the latest of those filings landed 15 May 2026.

Fund Action Shares Value
Viking Global Investors Held (±25%) +3.2% shares 6,652,448 $184.3M
AQR Capital Management Added +575.2% shares 5,946,858 $161.6M
Baker Bros. Advisors Held (±25%) −12.4% shares 4,867,723 $134.8M
Citadel Advisors Held (±25%) +10.1% shares 2,515,998 $69.7M
Marshall Wace Trimmed −35.0% shares 2,246,943 $62.2M
Maverick Capital New position 1,626,940 $45.1M
D. E. Shaw & Co. Added +252.2% shares 1,392,748 $38.6M
Point72 Asset Management New position 890,900 $24.7M
Man Group Trimmed −41.5% shares 852,204 $23.6M
Millennium Management Trimmed −32.9% shares 803,801 $22.3M

Source: SEC EDGAR 13F filings

ROIV fails-to-deliver

SEC CNS data

On 30 Jun 2026, 575 shares of ROIV failed to deliver (about $20K) — the latest of 2 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
30 Jun 2026 575 $20K <0.001%
29 Jun 2026 448,710 $15.3M 0.062%
22 Jun 2026 2,227 $70K <0.001%
15 Jun 2026 12,109 $364K 0.002%

Source: SEC fails-to-deliver (CNS) data